

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

GOTHENBURG, Sweden, 11 March 2026 – Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K., as well as letters of intent from a number of existing shareholders to exercise their respective pro rata portions in the warrant exercise, together representing 42 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants. The exercise period runs from 16 March 2026 up to and including 30 March 2026.

Isofol conducted a rights issue of units in June/July 2025. In connection with the rights issue, the Company issued a total of 39,863,928 warrants of series TO1. Each (1) warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company. The exercise price of the series TO1 warrants will be set at seventy (70) percent of the volume-weighted average price of the Company's share on Nasdaq Stockholm during the period from 2 March 2026 up to and including 13 March 2026. The exercise period for the series TO1 warrants runs from 16 March 2026 up to and including 30 March 2026. Final terms, including the exercise price of the warrants, will be announced on 13 March 2026 upon the conclusion of the pricing period.

Top guarantee commitment

The Company has entered into an agreement for a top guarantee provided free of charge with existing shareholder Solasia Pharma K.K. (the "Guarantor"). The top guarantee entails that the Guarantor has committed to guarantee 5.3 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants. The top guarantee lapses if the warrants are exercised to more than 100 percent of the total number. In the event the top guarantee is called upon, in whole or in part, the Guarantor will subscribe for shares in a directed new share issue in the Company at a subscription price corresponding to the exercise price of the series TO1 warrants as determined at that time. In the event the Guarantor's top guarantee is utilised, the board of directors of Isofol intends to exercise the authorisation granted at the Annual General Meeting on 21 May 2025 and resolve on a directed new share issue on the same terms as applicable to the exercise of TO1. The guarantee commitment has been agreed in writing but has not been secured by way of bank guarantee, blocked funds, pledge or similar arrangement, and accordingly there is a risk that the guarantee commitment may not be fulfilled.

Solasia Pharma K.K., listed on the Tokyo Stock Exchange, is Isofol's Japanese development and commercialisation partner. Since 2020, the two companies have in close partnership conducted clinical development of arfolitixorin in the Japanese market and will initiate a Phase II study in Japan during 2026.

Letters of intent

In addition, a number of Isofol's larger existing shareholders have submitted letters of intent to exercise their respective series TO1 warrants in accordance with their pro rata holdings. The same applies to the Company's board of directors and management. In aggregate, these letters of intent represent 36 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants. The letters of intent do not constitute binding commitments and accordingly there is a risk that they may not be fulfilled.

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States of America, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such disclosure, distribution or publication of this press release would be unlawful or require additional registration measure- or other measures. For more information, refer to the section "Important information" at the end of this press release.



In aggregate, the top guarantee commitment and letters of intent amount to 42 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants. Both the top guarantee and the letters of intent have been provided free of charge.

Advisors

ABG Sundal Collier AB is acting as financial advisor to the Company, Advokatfirman Vinge KB is legal advisor, to the Company and Aqurat Fondkommission is the issuing agent in connection with the administration of TO1.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, Chief Executive Officer

E-mail: petter.s.lindqvist@isofolmedical.com

Phone: +46 (0) 739 60 12 56

Margareta Hagman, Chief Financial Officer

E-mail: margareta.hagman@isofolmedical.com

Phone: +46 (0) 738 73 34 18

The information was submitted for publication, through the agency of the contact persons set out above, on 11 March 2026 at 15:30 CET.

About Isofol

Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com

Important information

The information in this press release does not contain and does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities in Isofol. No action has been taken, and no actions will be taken, to permit an offer to the public in any jurisdictions other than Sweden.

This release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Isofol. In order for investors to fully understand the potential risks and benefits associated with a decision to exercise warrants, any investment decision should only be made based on the information in the prospectus published by the Company on 17 June 2025 ("**Prospectus**"). Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an **advertisement**.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction in which such action would be unlawful or would be subject to legal restrictions or require any

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States of America, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such disclosure, distribution or publication of this press release would be unlawful or require additional registration measure- or other measures. For more information, refer to the section "Important information" at the end of this press release.



other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares, warrants or other securities in Isofol have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended (the "**Securities Act**") or the securities legislation of any state or other jurisdiction in the United States of America and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States.

Within the European Economic Area ("**EEA**"), no public offering of shares, warrants or other securities ("**Securities**") is made in other countries than Sweden. In other member states of the European Union ("**EU**"), such an offering of Securities may only be made in accordance with the exceptions in the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "**relevant persons**"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "*intend*", "*will*", "*assess*", "*expect*", "*may*", "*plan*", "*consider*", "*estimate*" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development, and the actual outcome could differ materially from the forward-looking statements.

This information, opinions and forward-looking statements contained in this press release applies only as of the date hereof and may be subject to change without notice. Isofol makes no commitment to publicly update or revise any forward-looking statements, future events or similar circumstances other than as required by applicable law.

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States of America, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such disclosure, distribution or publication of this press release would be unlawful or require additional registration measure- or other measures. For more information, refer to the section "Important information" at the end of this press release.



Since Isofol conducts essential services according to the Swedish Screening of Foreign Direct Investments Act (*Sw. lag (2023:560) om granskning av utländska direktinvesteringar*), certain investments in the Company's shares may require review by the Inspectorate of Strategic Products (ISP). More information on this can be found on the Company's website, <https://isofolmedical.com>.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.